Skip to main content

Disease Burden of Hepatocellular Carcinoma: A Global Perspective

Digestive Diseases and Sciences volume 64, pages 910–917 (2019)Cite this article

Abstract

Liver cancer is one of the leading causes of cancer-related mortality around the world. Hepatocellular carcinoma (HCC) is the primary cancer of the liver, accounting for the majority of liver cancers. The risk factors associated with HCC include chronic infections with HBV and HCV, alcoholic liver disease, and nonalcoholic fatty liver disease. Additionally, male patients have higher risk for than females, and the risk increases with older age. Mortality rates for HCC parallel its increasing incidence rates. In this context, incidence rate for HCC shows geographic variations in different parts of the world and is heavily affected by regional differences in risk factor for liver disease. The highest incidence rates for HCC are observed in Asia and Africa, while Europe and North America have lower rates. In fact, HBV is still regarded as the leading cause of HCC globally, while HCV is the most common cause of HCC in the USA. Recently, it has been suggested that HCC cases related to nonalcoholic fatty liver disease is on the rise, while the proportion of HCC attributed to alcoholic liver disease remains stable.

This is a preview of subscription content, access via your institution.

Access options

Buy single article

Instant access to the full article PDF.

USD 39.95

Price includes VAT (USA)
Tax calculation will be finalised during checkout.

References

  1. World Health Organisation, News room, fact sheets, cancer. In: WHO [Internet]. 1 Feb 2018 [cited 6 May 2018]. http://www.who.int/news-room/fact-sheets/detail/cancer

  2. Mittal S, El-Serag HB. Epidemiology of hepatocellular carcinoma: consider the population. J Clin Gastroenterol. 2013;47:S2–S6.

    Article  PubMed  PubMed Central  Google Scholar 

  3. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012;379:1245–1255.

    Article  PubMed  Google Scholar 

  4. Alazawi W, Cunningham M, Dearden J, Foster GR. Systematic review: outcome of compensated cirrhosis due to chronic hepatitis C infection. Aliment Pharmacol Ther. 2010;32:344–355.

    Article  CAS  PubMed  Google Scholar 

  5. Llovet JM, Bustamante J, Castells A, et al. Natural history of untreated nonsurgical hepatocellular carcinoma: rationale for the design and evaluation of therapeutic trials. Hepatology. 1999;29:62–67.

    Article  CAS  PubMed  Google Scholar 

  6. Ferlay J, Soerjomataram I, Dikshit R, et al. Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. Int J Cancer. 2015;136:E359–E386.

    Article  CAS  PubMed  Google Scholar 

  7. El-Serag HB. Hepatocellular carcinoma. N Engl J Med. 2011;365:1118–1127.

    Article  CAS  PubMed  Google Scholar 

  8. Ryerson AB, Eheman CR, Altekruse SF, et al. Annual Report to the Nation on the Status of Cancer, 1975–2012, featuring the increasing incidence of liver cancer. Cancer. 2016;122:1312–1337.

    Article  PubMed  Google Scholar 

  9. Younossi ZM, Otgonsuren M, Henry L, et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology. 2015;62:1723–1730.

    Article  CAS  PubMed  Google Scholar 

  10. Younossi Z, Stepanova M, Ong JP, et al. Nonalcoholic steatohepatitis is the fastest growing cause of hepatocellular carcinoma in liver transplant candidates. Clin Gastroenterol Hepatol. 2018;. https://doi.org/10.1016/j.cgh.2018.05.057.

    Article  PubMed  PubMed Central  Google Scholar 

  11. McGlynn KA, Petrick JL, London WT. Global epidemiology of hepatocellular carcinoma: an emphasis on demographic and regional variability. Clin Liver Dis. 2015;19:223–238.

    Article  PubMed  PubMed Central  Google Scholar 

  12. McGlynn KA, London WT. Epidemiology and natural history of hepatocellular carcinoma. Best Pract Res Clin Gastroenterol. 2005;19:3–23.

    Article  PubMed  Google Scholar 

  13. Bray F, Ferlay J, Laversanne M, et al. Cancer incidence in five continents: inclusion criteria, highlights from volume X and the global status of cancer registration. Int J Cancer. 2015;137:2060–2071.

    Article  CAS  PubMed  Google Scholar 

  14. Mitchell T, Armstrong GL, Hu DJ, Wasley A, Painter JA. The increasing burden of imported chronic hepatitis B—United States, 1974–2008. PLoS ONE. 2011;6:e27717.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  15. Kim D, Li AA, Perumpail BJ, et al. Changing trends in etiology- and ethnicity-based annual mortality rates of cirrhosis and hepatocellular carcinoma in the United States. Hepatology. 2018;. https://doi.org/10.1002/hep.30161.

    Article  PubMed  Google Scholar 

  16. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61:69–90.

    Article  PubMed  Google Scholar 

  17. Naugler WE, Sakurai T, Kim S, et al. Gender disparity in liver cancer due to sex differences in MyD88-dependent IL-6 production. Science. 2007;317:121–124.

    Article  CAS  PubMed  Google Scholar 

  18. Global Burden of Disease Liver Cancer Collaboration, Akinyemiju T, Abera S, et al. The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level: results from the global burden of disease study 2015. JAMA Oncol. 2017;3:1683–1691.

    Article  PubMed Central  Google Scholar 

  19. Chen C-J, Wang L-Y, Yu M-W. Epidemiology of hepatitis B virus infection in the Asia-Pacific region. J Gastroenterol Hepatol. 2000;15:E36. https://doi.org/10.1046/j.1440-1746.2000.02124.x.

    Article  Google Scholar 

  20. Bhaumik P. Epidemiology of viral hepatitis and liver diseases in India. Euroasian J Hepatogastroenterol. 2015;5:34–36.

    Article  PubMed  PubMed Central  Google Scholar 

  21. Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:S45–S57.

    Article  PubMed  Google Scholar 

  22. Wild CP, Gong YY. Mycotoxins and human disease: a largely ignored global health issue. Carcinogenesis. 2010;31:71–82.

    Article  CAS  PubMed  Google Scholar 

  23. Groopman JD, Kensler TW, Wild CP. Protective interventions to prevent aflatoxin-induced carcinogenesis in developing countries. Annu Rev Public Health. 2008;29:187–203.

    Article  PubMed  Google Scholar 

  24. Fan J-H, Wang J-B, Jiang Y, et al. Attributable causes of liver cancer mortality and incidence in china. Asian Pac J Cancer Prev. 2013;14:7251–7256.

    Article  PubMed  Google Scholar 

  25. Umemura T, Ichijo T, Yoshizawa K, Tanaka E, Kiyosawa K. Epidemiology of hepatocellular carcinoma in Japan. J Gastroenterol. 2009;44:102–107.

    Article  PubMed  Google Scholar 

  26. Vongsuvanh R, van der Poorten D, George J. Nonalcoholic fatty liver disease-related hepatocellular carcinoma: a sleeping tiger in the Asia Pacific. Hepatol Int. 2013;7:823–832.

    Article  PubMed  Google Scholar 

  27. Sun Z, Chen T, Thorgeirsson SS, et al. Dramatic reduction of liver cancer incidence in young adults: 28 year follow-up of etiological interventions in an endemic area of China. Carcinogenesis. 2013;34:1800–1805.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  28. Bridges JFP, Dong L, Gallego G, Blauvelt BM, Joy SM, Pawlik TM. Prioritizing strategies for comprehensive liver cancer control in Asia: a conjoint analysis. BMC Health Serv Res. 2012;12:376.

    Article  PubMed  PubMed Central  Google Scholar 

  29. Toyoda H, Kumada T, Tada T, Sone Y, Kaneoka Y, Maeda A. Characteristics and prognosis of patients with hepatocellular carcinoma after the year 2000 in Japan. J Gastroenterol Hepatol. 2011;26:1765–1771.

    Article  CAS  PubMed  Google Scholar 

  30. Chimed T, Sandagdorj T, Znaor A, et al. Cancer incidence and cancer control in Mongolia: results from the National Cancer Registry 2008–12. Int J Cancer. 2017;140:302–309.

    Article  CAS  PubMed  Google Scholar 

  31. Liu Y, Wu F. Global burden of aflatoxin-induced hepatocellular carcinoma: a risk assessment. Environ Health Perspect. 2010;118:818–824.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  32. Ladep NG. Why is the tumour different in Africa. Clinical dilemmas in primary liver cancer. Hoboken: Wiley; 2011:11–17.

    Book  Google Scholar 

  33. Tognarelli J, Ladep NG, Crossey MME, et al. Reasons why West Africa continues to be a hotbed for hepatocellular carcinoma. Niger Med J. 2015;56:231–235.

    Article  PubMed  PubMed Central  Google Scholar 

  34. Mokdad AA, Lopez AD, Shahraz S, et al. Liver cirrhosis mortality in 187 countries between 1980 and 2010: a systematic analysis. BMC Med. 2014;12:145.

    Article  PubMed  PubMed Central  Google Scholar 

  35. Kew MC. Epidemiology of hepatocellular carcinoma in sub-Saharan Africa. Ann Hepatol. 2013;12:173–182.

    Article  PubMed  Google Scholar 

  36. Yang JD, Mohamed EA, Aziz AOA, et al. Characteristics, management, and outcomes of patients with hepatocellular carcinoma in Africa: a multicountry observational study from the Africa Liver Cancer Consortium. Lancet Gastroenterol Hepatol. 2017;2:103–111.

    Article  PubMed  Google Scholar 

  37. Spearman CW, Sonderup MW. Health disparities in liver disease in sub-Saharan Africa. Liver Int. 2015;35:2063–2071.

    Article  PubMed  Google Scholar 

  38. Ascione A, Fontanella L, Imparato M, Rinaldi L, De Luca M. Mortality from cirrhosis and hepatocellular carcinoma in Western Europe over the last 40 years. Liver Int. 2017;37:1193–1201.

    Article  PubMed  Google Scholar 

  39. Blachier M, Leleu H, Peck-Radosavljevic M, Valla D-C, Roudot-Thoraval F. The burden of liver disease in Europe: a review of available epidemiological data. J Hepatol. 2013;58:593–608.

    Article  PubMed  Google Scholar 

  40. Taylor-Robinson SD, Toledano MB, Arora S, et al. Increase in mortality rates from intrahepatic cholangiocarcinoma in England and Wales 1968–1998. Gut. 2001;48:816–820.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  41. West J, Wood H, Logan RFA, Quinn M, Aithal GP. Trends in the incidence of primary liver and biliary tract cancers in England and Wales 1971–2001. Br J Cancer. 2006;94:1751.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  42. Ladep NG, Khan SA, Crossey MM, Thillainayagam AV, Taylor-Robinson SD, Toledano MB. Incidence and mortality of primary liver cancer in England and Wales: changing patterns and ethnic variations. World J Gastroenterol. 2014;20:1544–1553.

    Article  PubMed  PubMed Central  Google Scholar 

  43. Bertuccio P, Bosetti C, Levi F, Decarli A, Negri E, La Vecchia C. A comparison of trends in mortality from primary liver cancer and intrahepatic cholangiocarcinoma in Europe. Ann Oncol. 2013;24:1667–1674.

    Article  CAS  PubMed  Google Scholar 

  44. Bosetti C, Levi F, Boffetta P, Lucchini F, Negri E, La Vecchia C. Trends in mortality from hepatocellular carcinoma in Europe, 1980–2004. Hepatology. 2008;48:137–145.

    Article  PubMed  Google Scholar 

  45. Santi V, Buccione D, Di Micoli A, et al. The changing scenario of hepatocellular carcinoma over the last two decades in Italy. J Hepatol. 2012;56:397–405.

    Article  PubMed  Google Scholar 

  46. Pinter M, Hucke F, Zielonke N, Trauner M, Sieghart W, Peck-Radosavljevic M. Epidemiological trends of hepatocellular carcinoma in Austria. Dig Dis. 2014;32:664–669.

    Article  PubMed  Google Scholar 

  47. Schütte K, Kipper M, Kahl S, et al. Clinical characteristics and time trends in etiology of hepatocellular cancer in Germany. Digestion. 2013;87:147–159.

    Article  PubMed  Google Scholar 

  48. Sherman M. Hepatocellular carcinoma: epidemiology, risk factors, and screening. Semin Liver Dis. 2005;25:143–154.

    Article  PubMed  Google Scholar 

  49. Golabi P, Jeffers T, Younoszai Z, et al. Independent predictors of mortality and resource utilization in viral hepatitis related hepatocellular carcinoma. Ann Hepatol. 2017;16:555–564.

    Article  PubMed  Google Scholar 

  50. Zhu AX. Current status of hepatocellular carcinoma in the United States. Chin Clin Oncol. 2013;2:45.

    PubMed  Google Scholar 

  51. Altekruse SF, Henley SJ, Cucinelli JE, McGlynn KA. Changing hepatocellular carcinoma incidence and liver cancer mortality rates in the United States. Am J Gastroenterol. 2014;109:542–553.

    Article  PubMed  PubMed Central  Google Scholar 

  52. Espey DK, Wu X-C, Swan J, et al. Annual report to the nation on the status of cancer, 1975–2004, featuring cancer in American Indians and Alaska Natives. Cancer. 2007;110:2119–2152.

    Article  PubMed  Google Scholar 

  53. El-Serag HB. Epidemiology of viral hepatitis and hepatocellular carcinoma. Gastroenterology. 2012;142:1264–1273.e1.

    Article  PubMed  Google Scholar 

  54. Nordenstedt H, White DL, El-Serag HB. The changing pattern of epidemiology in hepatocellular carcinoma. Dig Liver Dis. 2010;42:S206–S214.

    Article  PubMed  PubMed Central  Google Scholar 

  55. Golabi P, Fazel S, Otgonsuren M, Sayiner M, Locklear CT, Younossi ZM. Mortality assessment of patients with hepatocellular carcinoma according to underlying disease and treatment modalities. Medicine. 2017;96:e5904.

    Article  PubMed  PubMed Central  Google Scholar 

  56. Sayiner M, Wymer M, Golabi P, Ford J, Srishord I, Younossi ZM. Presence of hepatitis C (HCV) infection in Baby Boomers with Medicare is independently associated with mortality and resource utilisation. Aliment Pharmacol Ther. 2016;43:1060–1068.

    Article  CAS  PubMed  Google Scholar 

  57. Turner BJ, Taylor BS, Hanson JT, et al. Implementing hospital-based baby boomer hepatitis C virus screening and linkage to care: strategies, results, and costs. J Hosp Med. 2015;10:510–516.

    Article  PubMed  Google Scholar 

  58. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epidemiology of nonalcoholic fatty liver disease-meta-analytic assessment of prevalence, incidence, and outcomes. Hepatology. 2016;64:73–84.

    Article  PubMed  Google Scholar 

  59. Sayiner M, Koenig A, Henry L, Younossi ZM. Epidemiology of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis in the United States and the rest of the world. Clin Liver Dis. 2016;20:205–214.

    Article  PubMed  Google Scholar 

  60. Kachuri L, De P, Ellison LF, Semenciw R, Advisory Committee on Canadian Cancer Statistics. Cancer incidence, mortality and survival trends in Canada, 1970–2007. Chronic Dis Inj Can. 2013;33:69–80.

    CAS  PubMed  Google Scholar 

  61. Jiang X, Pan SY, de Groh M, Liu S, Morrison H. Increasing incidence in liver cancer in Canada, 1972–2006: age-period-cohort analysis. J Gastrointest Oncol. 2011;2:223–231.

    PubMed  PubMed Central  Google Scholar 

  62. Chen Y, Yi Q, Mao Y. Cluster of liver cancer and immigration: a geographic analysis of incidence data for Ontario 1998–2002. Int J Health Geogr. 2008;7:28.

    Article  PubMed  PubMed Central  Google Scholar 

  63. Ramírez-Soto MC, Ortega-Cáceres G, Cabezas C. Trends in mortality burden of hepatocellular carcinoma, cirrhosis, and fulminant hepatitis before and after roll-out of the first pilot vaccination program against hepatitis B in Peru: an analysis of death certificate data. Vaccine. 2017;35:3808–3812.

    Article  PubMed  Google Scholar 

  64. Petrick JL, Braunlin M, Laversanne M, Valery PC, Bray F, McGlynn KA. International trends in liver cancer incidence, overall and by histologic subtype, 1978–2007. Int J Cancer. 2016;139:1534–1545.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  65. Ha J, Chaudhri A, Avirineni A, Pan J-J. Burden of hepatocellular carcinoma among hispanics in South Texas: a systematic review. Biomark Res. 2017;5:15.

    Article  PubMed  PubMed Central  Google Scholar 

  66. Luke C, Price T, Roder D. Epidemiology of cancer of the liver and intrahepatic bile ducts in an Australian population. Asian Pac J Cancer Prev. 2010;11:1479–1485.

    PubMed  Google Scholar 

  67. Carville KS, MacLachlan JH, Thursfield V, Cowie BC. Hepatocellular carcinoma over three decades in Victoria, Australia: epidemiology, diagnosis and trends, 1984-2013. Intern Med J. 2018;48:835–844.

    Article  PubMed  Google Scholar 

  68. Zhu RX, Seto W-K, Lai C-L, Yuen M-F. Epidemiology of hepatocellular carcinoma in the Asia-Pacific region. Gut Liver. 2016;10:332–339.

    Article  PubMed  PubMed Central  Google Scholar 

  69. Wallace MC, Preen DB, Short MW, Adams LA, Jeffrey GP. Hepatocellular carcinoma in Australia 1982–2014: increasing incidence and improving survival. Liver Int. 2018;. https://doi.org/10.1111/liv.13966.

    Article  PubMed  Google Scholar 

  70. Waziry R, Grebely J, Amin J, et al. Trends in hepatocellular carcinoma among people with HBV or HCV notification in Australia (2000–2014). J Hepatol. 2016;65:1086–1093.

    Article  PubMed  Google Scholar 

  71. Meredith I, Sarfati D, Ikeda T, Blakely T. Cancer in Pacific people in New Zealand. Cancer Causes Control. 2012;23:1173–1184.

    Article  PubMed  Google Scholar 

  72. Bianchi G, Loguercio C, Sgarbi D, et al. Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis. 2003;35:46–54.

    Article  CAS  PubMed  Google Scholar 

  73. Gandhi S, Khubchandani S, Iyer R. Quality of life and hepatocellular carcinoma. J Gastrointest Oncol. 2014;5:296–317.

    PubMed  PubMed Central  Google Scholar 

  74. Ahmed S, de Souza NN, Qiao W, Kasai M, Keem LJ, Shelat VG. Quality of life in hepatocellular carcinoma patients treated with transarterial chemoembolization. HPB Surg. 2016;2016:6120143.

    Article  PubMed  PubMed Central  Google Scholar 

  75. Chie W-C, Blazeby JM, Hsiao C-F, et al. Differences in health-related quality of life between European and Asian patients with hepatocellular carcinoma. Asia Pac J Clin Oncol. 2017;13:e304–e311.

    Article  PubMed  Google Scholar 

  76. Jin S, Yan L, Li B, et al. Quality of life and psychologic distress of recipients after adult living-donor liver transplantation (LDLT)—a study from mainland China. Transplant Proc. 2010;42:2611–2616.

    Article  CAS  PubMed  Google Scholar 

  77. Lei JY, Yan LN, Wang WT, Zhu JQ, Li DJ. Health-related quality of life and psychological distress in patients with early-stage hepatocellular carcinoma after hepatic resection or transplantation. Transplant Proc. 2016;48:2107–2111.

    Article  CAS  PubMed  Google Scholar 

  78. Sternby Eilard M, Hagström H, Mortensen KE, et al. Quality of life as a prognostic factor for survival in hepatocellular carcinoma. Liver Int. 2018;38:885–894.

    Article  PubMed  Google Scholar 

  79. Li L, Mo FK, Chan SL, et al. Prognostic values of EORTC QLQ-C30 and QLQ-HCC18 index-scores in patients with hepatocellular carcinoma—clinical application of health-related quality-of-life data. BMC Cancer. 2017;17:8.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  80. Mishra A, Otgonsuren M, Venkatesan C, Afendy M, Erario M, Younossi ZM. The inpatient economic and mortality impact of hepatocellular carcinoma from 2005 to 2009: analysis of the US nationwide inpatient sample. Liver Int. 2013;33:1281–1286.

    Article  PubMed  Google Scholar 

  81. Jinjuvadia R, Salami A, Lenhart A, Jinjuvadia K, Liangpunsakul S, Salgia R. Hepatocellular carcinoma: a decade of hospitalizations and financial burden in the United States. Am J Med Sci. 2017;354:362–369.

    Article  PubMed  PubMed Central  Google Scholar 

  82. Lang K, Danchenko N, Gondek K, Shah S, Thompson D. The burden of illness associated with hepatocellular carcinoma in the United States. J Hepatol. 2009;50:89–99.

    Article  PubMed  Google Scholar 

  83. El Khoury AC, Klimack WK, Wallace C, Razavi H. Economic burden of hepatitis C-associated diseases in the United States. J Viral Hepat. 2012;19:153–160.

    Article  PubMed  Google Scholar 

  84. Younossi ZM, Tanaka A, Eguchi Y, Henry L, Beckerman R, Mizokami M. Treatment of hepatitis C virus leads to economic gains related to reduction in cases of hepatocellular carcinoma and decompensated cirrhosis in Japan. J Viral Hepat. 2018;25:945–951.

    Article  CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Medicine, Center for Liver Diseases, Inova Fairfax Hospital, Falls Church, VA, USA

    Mehmet Sayiner & Zobair M. Younossi

  2. Betty and Guy Beatty Center for Integrated Research, Inova Health System, Falls Church, VA, USA

    Mehmet Sayiner, Pegah Golabi & Zobair M. Younossi

Authors
  1. Mehmet Sayiner
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Pegah Golabi
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Zobair M. Younossi
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Zobair M. Younossi.

Ethics declarations

Conflict of interest

Dr. Younossi is a consultant to BMS, Gilead, AbbVie, Intercept, NovoNordisk, Viking, Terns and Quest. All other authors have no conflict of interest to disclose.

Additional information

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Sayiner, M., Golabi, P. & Younossi, Z.M. Disease Burden of Hepatocellular Carcinoma: A Global Perspective. Dig Dis Sci 64, 910–917 (2019). https://doi.org/10.1007/s10620-019-05537-2

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s10620-019-05537-2

Keywords

  • Hepatocellular carcinoma
  • Epidemiology
  • Hepatitis B
  • Hepatitis C